Wescott Financial Advisory Group LLC Purchases Shares of 853 Penumbra, Inc. (NYSE:PEN)

Wescott Financial Advisory Group LLC acquired a new position in shares of Penumbra, Inc. (NYSE:PEN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 853 shares of the company’s stock, valued at approximately $203,000.

Several other large investors also recently made changes to their positions in PEN. UMB Bank n.a. raised its position in Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after acquiring an additional 70 shares in the last quarter. Huntington National Bank increased its stake in shares of Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after purchasing an additional 154 shares during the last quarter. Mather Group LLC. increased its stake in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after purchasing an additional 208 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after purchasing an additional 75 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Penumbra by 160.8% in the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock valued at $106,000 after purchasing an additional 275 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Buying and Selling at Penumbra

In related news, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the sale, the executive vice president now owns 66,539 shares in the company, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Thomas Wilder sold 360 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the transaction, the director now owns 4,533 shares of the company’s stock, valued at approximately $1,199,341.14. This represents a 7.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,236 shares of company stock valued at $31,222,390 in the last ninety days. 5.00% of the stock is currently owned by company insiders.

Penumbra Price Performance

Penumbra stock opened at $262.37 on Friday. The firm has a market cap of $10.11 billion, a PE ratio of 771.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The stock’s fifty day moving average price is $274.48 and its two-hundred day moving average price is $245.21. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PEN has been the topic of several research analyst reports. Truist Financial upped their price objective on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Wells Fargo & Company raised their price target on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. upped their price objective on shares of Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Piper Sandler restated an “overweight” rating and set a $330.00 target price (up previously from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Finally, Robert W. Baird upped their price target on shares of Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Penumbra currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.